BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30

• BioMidwest

  NewLink Genetics to Present at Upcoming Investor Conferences

  June 7, 2010

   · 

  1 min read
• Smith & Nephew Inc. Launches Clinical Hotline for Patients Using RENASYS(TM) Negative Pressure Wound Therapy Systems

  June 7, 2010

   · 

  3 min read
• Business

  Proteonomix, Inc. (PROT) Retains Wolfe Axelrod Weinberger Associates LLC as Its Investor Relations Agency

  June 7, 2010

   · 

  2 min read
• Drug Development

  AVEO Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trial Evaluating SCH 900105 (AV-299) in Non-Small Cell Lung Cancer

  June 7, 2010

   · 

  1 min read
• Drug Development

  Abraxis BioScience, Inc. Release: Results of Phase 3 ABRAXANE(R) Combination Trial In First-Line Non-Small Cell Lung Cancer Show 31 Percent Improvement In Response Rate Compared With Taxol Combination

  June 7, 2010

   · 

  1 min read
• Drug Development

  Millennium: The Takeda Oncology Company Release: VELCADE(R) (bortezomib) Data in Relapsed or Refractory Amyloidosis Presented at American Society of Clinical Oncology Annual Meeting

  June 7, 2010

   · 

  1 min read
• Drug Development

  Genta Incorporated Release: Pooled Results of Early Endpoints from Phase 3 Trials of Genasense(R) in Advanced Melanoma Presented at American Society of Clinical Oncology

  June 7, 2010

   · 

  1 min read
• Drug Development

  Millennium: The Takeda Oncology Company Release: New Clinical Data on Millennium Solid Tumor Compounds Presented at American Society of Clinical Oncology

  June 7, 2010

   · 

  1 min read
• Drug Development

  Bristol-Myers Squibb Company Release: Four-Year Follow-Up Data for SPRYCEL(R) (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec(R)

  June 7, 2010

   · 

  1 min read
• Drug Development

  The Angeles Clinic and Research Institute Announces Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-Treated Patients with Metastatic Melanoma

  June 7, 2010

   · 

  1 min read